NEW HAVEN — Antibiotics developer BioRelix received a $269,160 follow-on investment from Connecticut Innovations Inc. (CII) for continued research.

The company is developing antibiotics using a new riboswitch-based drug discovery platform. Riboswitches are short stretches of mRNA that bind molecules and control genes essential for the survival of many human pathogens. The method was discovered in the laboratory by Yale biology professor Ronald R. Breaker.

The BioRelix team includes former Yale and Bayer Pharmaceuticals scientists, and has secured technology licenses from Yale. The company last received $500,000 from CII in December. The latest round comes from CII’s Eli Whitney Fund and is part of a $2.5 million funding round.